Pharmaceuticals

Eli Lilly signs agreement to acquire Morphic for $3.2 billion

bexib
By bexib 0 Min Read

The acquisition of Morphic is intended to strengthen treatment options for inflammatory bowel disease and expand Lilly’s gastroenterology portfolio.

You Might Also Like

QuantaMatrix’s AMR inspection technology is backed by research paper in Nature magazine

Immunibio Initiates Study to Evaluate Combination of Anktiva and AdHER2DC Cancer Vaccine Against Endometrial Cancer

Pharma Pulse 8/5/24: Pharmacists step up RSV care, China aims to launch national internet ID system, and more

Pharma Pulse 9/9/24: How prepared is the pharmaceutical industry for DSCSA compliance? Companies are leveraging VR in the workplace, etc.

FDA approves Farxiga to improve blood sugar control in pediatric patients with type 2 diabetes

Share This Article
Previous Article The return of pointless competition
Next Article The impact on trucking companies and the importance of liability insurance
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Goldman launches three-year technology investment plan
Banking
Wells Fargo is committed to risk infrastructure and efficiency initiatives
Banking
Creative Engineering Under Pressure by Jesse Velez and Ben Eadie
Manufacturing
Chart: Global Retail CEOs’ Q4 2024 Outlook
Retail & E-commerce